Summary:
This week, we explore two powerful forces shaping the future of clinical laboratories — the policy storm around the RESULTS Act vs. PAMA and the economic slowdown rippling through major IVD and automation vendors. Together, they reveal how reimbursement pressure and upstream supply constraints could redefine what stability looks like for hospital and independent labs alike.
Segments:
- The RESULTS Act & PAMA Cliff – What Congress is trying to fix, what happens if they don’t, and how labs can model 2026 scenarios now.
- Vendor Slowdown & Supply Chain Shifts – What’s driving slower product rollouts, higher reagent costs, and what labs can do to stay ahead.
Key Takeaways:
- Plan for the cliff — model 10–15% reductions on core tests for 2026.
- Push for the fix — advocacy still matters; RESULTS could cap cuts at 5%.
- Watch vendor behavior — slower innovation and rising costs are early warning signs.
- Build resilience — diversify supply, automate intelligently, and align with finance.
Host: Dr. Chris Zahner
Produced by: LabReflex Media
Tags: #ClinicalLaboratory #PAMA #RESULTSAct #Diagnostics #LabOperations #HealthcarePolicy
